Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Telix Reports Second Quarter 2022 Financial Results
2022-07-21 08:34
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
2022-07-11 08:26
Kevin Richardson appointed as CEO, Telix Americas
2022-07-11 08:13
Telix and Invicro Advance AI Partnership
2022-06-14 19:00
Telix and Invicro Advance AI Partnership
2022-06-14 14:21
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network
2022-06-13 19:11
Telix and RefleXion Expand Partnership for Prostate Cancer Treatment
2022-06-10 19:00
Telix to Present at Jefferies Healthcare Conference
2022-06-07 19:00
Telix Showcasing Innovation in Theranostics at SNMMI
2022-06-07 05:00
Illuccix® Granted Transitional Pass-Through Payment Status
2022-05-31 19:00
Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.
2022-05-30 08:02
First Patient Dosed in Phase II Renal Cancer Theranostics Study
2022-05-05 05:00
Telix Further Strengthens European Distribution Network for Illuccix
2022-04-22 07:10
First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
2022-04-14 19:00
ProstACT Update: TARGET Study Ethics Approval
2022-04-12 07:47
Telix Pharmaceuticals Announces Licence Agreement with Lilly for Olaratumab
2022-04-11 06:51
PSMA-PET Imaging to be Funded through Medicare in Australia from July 2022
2022-04-06 12:47
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
2022-04-04 09:13
Commercial Launch: Illuccix® Now Available to Order in the United States
2022-04-04 07:06
Change of Composition of the Telix Board of Directors
2022-03-31 07:11
1
2
3
4
5
6